Supportive therapy in multiple myeloma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-540-85772-3_15PMID 21509692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ocular Adverse Effects Associated with Systemic Medications

  2012cited by this paper
• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  2010cited by this paper
• Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: multiple myeloma.

  2009cited by this paper
• Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

  2009cited by this paper
• Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

  2008cited by this paper
• Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cited by this paper
• Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature*

  2008cited by this paper
• Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cited by this paper
• Pathogenesis and treatment of renal failure in multiple myeloma

  2008cited by this paper
• Hematopoietic growth factors: ESMO recommendations for the applications.

  2008cited by this paper
• September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

  2008cited by this paper
• Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma

  2008cited by this paper
• Duration of red-cell storage and complications after cardiac surgery.

  2008cited by this paper
• Hematopoietic growth factors: ESMO recommendations for the applications.

  2008cited by this paper
• Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

  2008cited by this paper
• EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

  2007cited by this paper
• Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance

  2007cited by this paper
• American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

  2007cited by this paper
• Ocular adverse effects associated with systemic medications : recognition and management.

  2007cited by this paper
• Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

  2007cited by this paper
• Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients

  2006cited by this paper
• Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY

  2006cited by this paper
• Perioperative blood transfusions and recurrence of colorectal cancer

  2006cited by this paper
• Recombinant Human Erythropoietin Is Associated with Increased Overall Survival in Patients with Multiple Myeloma

  2006cited by this paper
• Iron Metabolism and Iron Supplementation in Anemia of Cancer

  2006cited by this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cited by this paper
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

  2006cited by this paper
• Lenalidomide and venous thrombosis in multiple myeloma.

  2006cited by this paper
• Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

  2006cited by this paper
• Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

  2006cited by this paper
• Plasma Exchange When Myeloma Presents as Acute Renal Failure

  2005cited by this paper
• Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis

  2005cited by this paper
• Renal, hematologic and infectious complications in multiple myeloma.

  2005cited by this paper
• Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.

  2005cited by this paper
• Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

  2005cited by this paper
• Myeloma bone disease: pathophysiology and management.

  2005cited by this paper
• Impact of epoetin‐β on survival of patients with lymphoproliferative malignancies: long‐term follow up of a large randomized study *

  2005cited by this paper
• Recommendations for zoledronic acid treatment of patients with bone metastases.

  2005cited by this paper
• Renal safety of ibandronate.

  2005cited by this paper
• The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

  2005cited by this paper
• Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

  2005cited by this paper
• Evaluation of Traditional and Novel Predictive Markers of Anemia Response to Recombinant Human Erythropoietin (rh-Epo) in Patients with Multiple Myeloma and Lymphoma: Emerging Role of Functional Iron Deficiency.

  2004cited by this paper
• Perioperative blood transfusions for the recurrence of colorectal cancer.

  2004cited by this paper
• Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study

  2004cited by this paper
• Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β2‐microglobulin in multiple myeloma

  2003cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study

  2003cited by this paper
• Once‐weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

  2003cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myeloma

  2002cited by this paper
• Myeloma interacts with the bone marrow microenvironment 
to induce osteoclastogenesis and is dependent on osteoclast activity

  2002cited by this paper
• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  2002cited by this paper
• Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

  2002cited by this paper
• Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

  2002cited by this paper
• Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

  2002cited by this paper
• COX-2 inhibitors: cancer trials test new uses for pain drug.

  2002cited by this paper
• Anemia of hematologic malignancies: what are the treatment options?

  2002cited by this paper
• Bisphosphonates in multiple myeloma.

  2002cited by this paper
• A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

  2001cited by this paper
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  2001cited by this paper
• Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program.

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

  2001cited by this paper
• Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.

  2001cited by this paper
• Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases

  2001cited by this paper
• Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.

  2001cited by this paper
• Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

  2001cited by this paper
• Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

  2001cited by this paper
• Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

  2001cited by this paper
• Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma

  2001cited by this paper
• Dosing regimens and main adverse events of bisphosphonates.

  2001cited by this paper
• Bisphosphonates in multiple myeloma.

  2001cited by this paper
• Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.

  1999cited by this paper
• Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato oncological patients.

  1998cited by this paper
• Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

  1998cited by this paper
• The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

  1998cited by this paper
• Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

  1998cited by this paper
• The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy

  1998cited by this paper
• In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

  1998cited by this paper
• Long‐term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

  1998cited by this paper
• Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial

  1998cited by this paper
• Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

  1998cited by this paper
• Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

  1998cited by this paper
• A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

  1998cited by this paper
• The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma.

  1998cited by this paper
• Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation

  1997cited by this paper
• Breast cancer and osteolytic metastases: Can bisphosphonates help?

  1997cited by this paper
• Clinical results of recombinant erythropoietin in transfusion‐dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis

  1997cited by this paper
• Surgical management of invasive pulmonary aspergillosis in neutropenic patients.

  1997cited by this paper
• [Prevention of infections in patients with lymphoproliferative syndromes and myeloma by nebulization of an IgA concentrate].

  1997cited by this paper
• Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity

  1997cited by this paper
• Pathogenesis and management of bone lesions in multiple myeloma.

  1997cited by this paper
• Erythropoietin and iron.

  1997cited by this paper
• A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate.

  1997cited by this paper
• Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia

  1996cited by this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma : A randomized multicenter study

  1996cited by this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

  1996cited by this paper

• Mieloma múltiple: consideraciones especiales al diagnóstico

  2021cites this paper
• Anaesthesia for fixation of repeated pathological fractures in a patient with multiple myeloma

  2017cites this paper
• Cytokines Behavior in Multiple Myeloma Patients during Zoledronic Acid Treatment

  2017cites this paper
• Biological markers and treatment as prognostic factors in multiple myeloma

  2015influential citation
• Perioperative considerations in the management of a patient with multiple myeloma undergoing aortic valve replacement.

  2015cites this paper
• Oncology Pharmacy Management and the Evolving Role of Managed Care: Recommendations for a Changing Environment with a Focus on Multiple Myeloma

  2012cites this paper